The FDA moved fast after the EO. But ibogaine is still Schedule I, and the trial that got cleared isn't for ibogaine. Here's the honest 60-day accounting.
Read the article →
The FDA pathway is the clearest it's ever been. Nobody is talking about who ends up owning the medicine when it gets there.
Jim Koch's neurologist told him not to go to Mexico. The data wasn't there and the risk was real. Jim went anyway. One year later, he hasn't taken a single Parkinson's medication.
It sits at the gas station counter next to the energy drinks. One clinic reports it has overtaken fentanyl as their most common presenting addiction.
Diane Hall opened an Instagram account for one reason: to find the thing that might still save her son.
Editorial profiles of every legitimate ibogaine clinic — built from interviews, not intake forms. Who they are, what they do, and how they differ.
Trials, evidence, and scholarship — from peer-reviewed clinical research to ethnobotany, anthropology, and the field history nobody teaches.
Federal scheduling, state legislation, and international law — in real time. The landscape is moving. We follow it so you don't have to.
The questions real people are actually asking — about safety, legality, cardiac risk, what to look for in a clinic, and what to expect. Answered with evidence.
What ibogaine is and what treatment actually looks like — from the first moment of curiosity through preparation, screening, and the session itself.
Life after ibogaine. Integration practices, the difficult emotions that surface, peer support resources, therapist directories, and the long work of rebuilding.